Summary 16
Although several clinical trials are now underway to test possible therapies, the worldwide 17 response to the COVID-19 outbreak has been largely limited to monitoring/containment. We 18 report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-19 spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with 20 a single addition to Vero-hSLAM cells 2 hours post infection with SARS-CoV-2 able to 21 effect ~5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further 22 investigation for possible benefits in humans. 23 24 25
Ivermectin is an FDA-approved broad spectrum anti-parasitic agent 1 that in recent years we, 27 along with other groups, have shown to have anti-viral activity against a broad range of 28 viruses 2-5 in vitro. Originally identified as an inhibitor of interaction between the human 29 immunodeficiency virus-1 (HIV-1) integrase protein (IN) and the importin (IMP) α/β1 30 heterodimer responsible for IN nuclear import 6 , Ivermectin has since been confirmed to 31 inhibit IN nuclear import and HIV-1 replication 5 . Other actions of ivermectin have been 32 reported 7 , but ivermectin has been shown to inhibit nuclear import of host (eg. 8, 9 ) and viral 33 proteins, including simian virus SV40 large tumour antigen (T-ag) and dengue virus (DENV) 34 non-structural protein 5 5, 6 . Importantly, it has been demonstrated to limit infection by RNA 35 viruses such as DENV 1-4 4 , West Nile Virus 10 , Venezuelan equine encephalitis virus 36 (VEEV) 3 and influenza 2 , with this broad spectrum activity believed to be due to the reliance 37 by many different RNA viruses on IMPα/β1 during infection 11, 12 . Ivermectin has similarly 38 been shown to be effective against the DNA virus pseudorabies virus (PRV) both in vitro and 39 in vivo, with ivermectin treatment shown to increase survival in PRV-infected mice 13 . 40
Efficacy was not observed for ivermectin against Zika virus (ZIKV) in mice, but the authors 41 acknowledged that study limitations justified re-evaluation of ivermectin's anti-ZIKV 42 activity 14 . Finally, ivermectin was the focus of a phase III clinical trial in Thailand in 2014-43 2017, against DENV infection, in which a single daily oral dose was observed to be safe and 44 resulted in a significant reduction in serum levels of viral NS1 protein, but no change in 45 viremia or clinical benefit was observed (see below) 15 . 46
The causative agent of the current COVID-19 pandemic, SARS-CoV-2, is a single 47 stranded positive sense RNA virus that is closely related to severe acute respiratory syndrome 48 coronavirus (SARS-CoV). Studies on SARS-CoV proteins have revealed a potential role for 49
IMPα/β1 during infection in signal-dependent nucleocytoplasmic shutting of the SARS-CoV 50
Nucleocapsid protein [16] [17] [18] , that may impact host cell division 19, 20 . In addition, the SARS-CoV 51 accessory protein ORF6 has been shown to antagonize the antiviral activity of the STAT1 52 transcription factor by sequestering IMPα/β1 on the rough ER/Golgi membrane 21 . Taken 53 together, these reports suggested that ivermectin's nuclear transport inhibitory activity may 54 be effective against SARS-CoV-2. 55
To test the antiviral activity of ivermectin towards SARS-CoV-2, we infected 56
Vero/hSLAM cells with SARS-CoV-2 isolate Australia/VIC01/2020 at an MOI of 0.1 for 2 57 h, followed by the addition of 5 µM ivermectin. Supernatant and cell pellets were harvested 58 at days 0-3 and analysed by RT-PCR for the replication of SARS-CoV-2 RNA ( Fig. 1A/B ). indicating that ivermectin treatment resulted in the effective loss of essentially all viral 65 material by 48 h. Consistent with this idea, no further reduction in viral RNA was observed at 66 72 h. As we have observed previously 3-5 , no toxicity of ivermectin was observed at any of the 67 timepoints tested, in either the sample wells or in parallel tested drug alone samples. 68
To further determine the effectiveness of ivemectin, cells infected with SARS-CoV-2 were 69 treated with serial dilutions of ivermectin 2 h post infection and supernatant and cell pellets 70 collected for real-time RT-PCR at 48 h (Fig. 1C/D) . As above, a >5000 reduction in viral 71
RNA was observed in both supernatant and cell pellets from samples treated with 5 µM 72 ivermectin at 48 h, equating to a 99.98% reduction in viral RNA in these samples. Again, no 73 toxicity was observed with ivermectin at any of the concentrations tested. The IC50 of 74 ivermectin treatment was determined to be ~2µM under these conditions. Underlining the 75 fact that the assay indeed specifically detected SARS-CoV-2, RT-PCR experiments were repeated using primers specific for the viral RdRp gene (Fig. 1E/F ) rather than the E gene 77 (above), with nearly identical results observed for both released (supernatant) and cell-78 associated virus. 79
Taken together these results demonstrate that ivermectin has antiviral action against 80 the SARS-CoV-2 clinical isolate in vitro, with a single dose able to control viral replication 81 within 24-48 h in our system. We hypothesise that this is likely through inhibiting IMPα/β1-82 mediated nuclear import of viral proteins (Fig. 1G) , as shown for other RNA viruses 4, 5, 10 ; 83 confirmation of this mechanism in the case of SARS-CoV-2, and identification of the specific 84 SARS-CoV-2 and/or host component(s) impacted (see 10 ) is an important focus future work 85 in this laboratory. Ultimately, development of an effective anti-viral for SARS-CoV-2, if 86
given to patients early in infection, could help to limit the viral load, prevent severe disease 87 progression and limit person-person transmission. Benchmarking testing of ivermectin 88 against other potential antivirals for SARS-CoV-2 with alternative mechanisms of action 22-26 89 would thus be important as soon as practicable. This Brief Report raises the possibility that 90 ivermectin could be a useful antiviral to limit SARS-CoV-2, in similar fashion to those 91 already reported [22] [23] [24] [25] [26] ; until one of these is proven to be beneficial in a clinical setting, all 92 should be pursued as rapidly as possible. 93
Ivermectin has an established safety profile for human use 1, 12, 27 , and is FDA-94 approved for a number of parasitic infections 1, 27 . Importantly, recent reviews and meta-95 analysis indicate that high dose ivermectin has comparable safety as the standard low-dose 96 treatment, although there is not enough evidence to make conclusions about the safety profile 97 in pregnancy 28, 29 . The critical next step in further evaluation for possible benefit in COVID-98 19 patients will be to examine a multiple addition dosing regimen that mimics the current 99 approved usage of ivermectin in humans. As noted, ivermectin was the focus of a recent 100 phase III clinical trial in dengue patients in Thailand, in which a single daily dose was found 101 to be safe but did not produce any clinical benefit. However, the investigators noted that an 102 improved dosing regimen might be developed, based on pharmacokinetic data 15 . Although 103 DENV is clearly very different to SARS-CoV-2, this trial design should inform future work 104 going forward. Altogether the current report, combined with a known-safety profile, 105 demonstrates that ivermectin is worthy of further consideration as a possible SARS-CoV-2 106 antiviral. 107 108 Methods 109
Cell culture, viral infection and drug treatment 110
Vero/hSLAM cells 30 were maintained in Earle's Minimum Essential Medium (EMEM) 111 containing 7% Fetal Bovine Serum (FBS) (Bovogen Biologicals, Keilor East, AUS) 2 mM L-112
Glutamine, 1 mM Sodium pyruvate, 1500 mg/L sodium bicarbonate, 15 mM HEPES and 0.4 113 mg/ml geneticin at 37°C, 5% CO 2 . Cells were seeded into 12-well tissue culture plates 24 h 114 prior to infection with SARS-CoV-2 (Australia/VIC01/2020 isolate) at an MOI of 0.1 in 115 infection media (as per maintenance media but containing only 2% FBS) for 2 h. Media 116 containing inoculum was removed and replaced with 1 mL fresh media (2% FBS) containing 117
Ivermectin at the indicated concentrations or DMSO alone and incubated as indicated for 0-3 118 days. At the appropriate timepoint, cell supernatant was collected and spun for 10 min at 119 6,000g to remove debris and the supernatant transferred to fresh collection tubes. The cell 120 monolayers were collected by scraping and resuspension into 1 mL fresh media (2% FBS). 
